Linda Porter

TL;DR: A consensus meeting was convened by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) to provide recommendations for interpreting clinical importance of treatment outcomes in clinical trials of the efficacy and effectiveness of chronic pain treatments as discussed by the authors.

TL;DR: The prevalence of chronic pain and high-impact chronic pain in the United States is analyzed to help differentiate persons with limitations in major life domains from those who maintain normal life activities despite chronic pain, providing a better understanding of the population in need of pain services.

TL;DR: In this paper, the authors present recommendations for the major components of confirmatory chronic pain clinical trials, including participant selection, trial phases and duration, treatment groups and dosing regimens, and types of trials.

TL;DR: Evidence is presented on the most promising phenotypic characteristics of patients that are most predictive of individual variation in analgesic treatment outcomes, and the measurement tools that are best suited to evaluate these characteristics.

TL;DR: There were no significant differences in headache frequency or headache‐related disability in childhood and adolescent migraine with amitriptyline, topiramate, or placebo over a period of 24 weeks, and the active drugs were associated with higher rates of adverse events.